This document id is 30160001 .
1.00: (This document id; is; 30160001)

Tumors in the head and neck region include a heterogeneous group of carcinomas whose treatment has advanced in recent years .
0.99: (Tumors in the head region; include; a heterogeneous group of carcinomas whose treatment has advanced in recent years)
0.90: (a heterogeneous group of carcinomas; has advanced; in recent years)
0.99: (Tumors in the neck region; include; a heterogeneous group of carcinomas whose treatment has advanced in recent years)

This document id is 30160002 .
1.00: (This document id; is; 30160002)

Tumors in the head and neck region comprise a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years .
1.00: (Tumors in the head region; comprise; a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years)
0.45: (heterogeneous group carcinomas therapy progress; has been observed; in recent years)
1.00: (Tumors in the neck region; comprise; a heterogeneous group of carcinomas for whose therapy progress has been observed in recent years)
0.47: (carcinomas progress; has been observed; in recent years)

This document id is 30160011 .
1.00: (This document id; is; 30160011)

At the same time , however , there has been a shift in risk factors from a decrease in tobacco- and alcohol-associated cancers to an increase in human papillomavirus-related carcinomas .

This document id is 30160012 .
1.00: (This document id; is; 30160012)

At the same time , there has been a shift in risk factors in the form of a decrease in tobacco- and alcohol-associated cancers to an increase in human papillomavirus-related carcinomas .

This document id is 30160021 .
1.00: (This document id; is; 30160021)

This shift changes the understanding of the disease , its therapy , and the life expectancy of those affected .
1.00: (This shift; changes; the understanding of the disease)
1.00: (This shift; changes; its therapy)
1.00: (This shift; changes; the life expectancy of those)
1.00: (those; affected; )

This document id is 30160022 .
1.00: (This document id; is; 30160022)

This changes the understanding of the disease , its therapy and the life expectancy of those affected .
1.00: (This; changes; the understanding of the disease)
1.00: (This; changes; its therapy)
1.00: (This; changes; the life expectancy of those)
1.00: (those; affected; )

This document id is 30160031 .
1.00: (This document id; is; 30160031)

This work focuses on radiation therapy , a treatment option with possible short- and long-term complications , and the resulting consequences for the patients ' quality of life .
1.00: (This work; focuses; on the resulting consequences for the patients ' quality of life)
1.00: (This work; focuses; on radiation therapy)

This document id is 30160032 .
1.00: (This document id; is; 30160032)

The focus here will be on radiation treatment , a treatment option with potential short- and long-term complications and the resulting consequences for patients ' quality of life .
1.00: (The focus here; will be; on radiation treatment)

This document id is 30160041 .
1.00: (This document id; is; 30160041)

Furthermore , we show which supportive measures can be taken during and after radiation therapy with the help of clinical pharmacists .
1.00: (we; show; which supportive measures can be taken during radiation therapy with the help of clinical pharmacists)
0.93: (which supportive measures; can be taken; during radiation therapy with the help of clinical pharmacists)
1.00: (we; show; which supportive measures can be taken after radiation therapy with the help of clinical pharmacists)
0.87: (which supportive measures; can be taken; after radiation therapy with the help of clinical pharmacists)

This document id is 30160042 .
1.00: (This document id; is; 30160042)

Furthermore , it will be shown which supportive measures can be taken during and after radiation treatment with the participation of clinical pharmacists .
1.00: (it; will be shown; )
0.15: (which supportive measures; can be taken; during radiation treatment with the participation of clinical pharmacists)
0.19: (which supportive measures; can be taken; after radiation treatment with the participation of clinical pharmacists)

This document id is 30170001 .
1.00: (This document id; is; 30170001)

Daunorubicin has been established as important cornerstone in ALL- and AML-treatment since many years .
1.00: (Daunorubicin; has been established; as important cornerstone in ALL- and AML-treatment since many years)

This document id is 30170002 .
1.00: (This document id; is; 30170002)

The anthracycline daunorubicin has been an integral part of ALL and AML treatment for many years .
1.00: (The anthracycline daunorubicin; has been; an integral part of ALL treatment for many years)
1.00: (The anthracycline daunorubicin; has been; an integral part of AML treatment for many years)

This document id is 30170011 .
1.00: (This document id; is; 30170011)

Its metabolite daunorubicinol does not contribute to antineoplastic activities of the anthracycline , however , it may have a potential impact on drug 's cardiotoxicity .
1.00: (it; may have; a potential impact on drug 's cardiotoxicity)
1.00: (Its metabolite daunorubicinol; does not contribute; to antineoplastic activities of the anthracycline)

This document id is 30170012 .
1.00: (This document id; is; 30170012)

The metabolite daunorubicinol plays less of a role in the antineoplastic effect , but probably more in the potential cardiotoxicity of the cytostatic .
1.00: (The metabolite daunorubicinol; plays; less of a role in the antineoplastic effect)
0.97: (The metabolite daunorubicinol; plays; more in the potential cardiotoxicity of the cytostatic)

This document id is 30170021 .
1.00: (This document id; is; 30170021)

Current guidelines in Germany consider a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min which ( 1 ) is in contrast to FDA-based guidelines , and ( 2 ) which is somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin and doxorubicin are compared with each other .
1.00: (Current guidelines in Germany; consider; a daunorubicin dose reduction by 50 % in case of individual GFR between 30 and 50 ml/min)
1.00: (30 and 50 ml/min; is; in contrast to FDA-based guidelines)
0.92: (30 and 50 ml/min; is; somewhat confusing when the clinical pharmacokinetic behaviour of daunorubicin are compared with each other)
1.00: (the clinical pharmacokinetic behaviour of daunorubicin; are compared; with each other)
0.91: (30 and 50 ml/min; is; somewhat confusing when the clinical pharmacokinetic behaviour of doxorubicin are compared with each other)
1.00: (the clinical pharmacokinetic behaviour of doxorubicin; are compared; with each other)

This document id is 30170022 .
1.00: (This document id; is; 30170022)

The currently filed guidelines for dose modification stipulate that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min .
0.99: (The currently filed guidelines for dose modification; stipulate; that the anthracycline should only be used at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min)
0.97: (the anthracycline; should only be used; at 50 % of the usual dose already at a glomerular filtration rate ( GFR ) between 50 ml/min and 30 ml/min)

This document id is 30170031 .
1.00: (This document id; is; 30170031)

As a consequence , a leukemia patient may receive daunorubicin full dose in the US , and 50 % of curative dose in Germany in case of e.g . GFR 43 ml/min .
0.95: (a leukemia patient; may receive; daunorubicin full dose in the US)
0.51: (a leukemia patient; may 50; % of curative dose in Germany in case of . GFR 43 e.g ml/min)

This document id is 30170032 .
1.00: (This document id; is; 30170032)

This requirement is irritating , considering that ( 1 ) the FDA has not provided a corresponding recommendation to date , and ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin and doxorubicin .
1.00: (This requirement; is; irritating)
0.14: (This requirement; considering; that ( 1 ) the FDA has not provided a corresponding recommendation to date)
0.98: (the FDA; has not provided; a corresponding recommendation to date)
1.00: (This requirement; considering; that ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between daunorubicin)
0.93: (( 2 ) recent work; has identified; very large clinical pharmacokinetic parallels between daunorubicin)
1.00: (This requirement; considering; that ( 2 ) recent work has identified very large clinical pharmacokinetic parallels between doxorubicin)
0.93: (( 2 ) recent work; has identified; very large clinical pharmacokinetic parallels between doxorubicin)

This document id is 30170041 .
1.00: (This document id; is; 30170041)

Thus , a revised assessment of current guidelines on a regulatory level is of great interest for clinical oncologist .
1.00: (a revised assessment of current guidelines on a regulatory level; is; of great interest for clinical oncologist)

This document id is 30170042 .
1.00: (This document id; is; 30170042)

Thus , a leukemia patient with a GFR of 43 ml/min would receive only 50 % of the curatively scheduled dose in Germany compared with the United States .
0.69: (a leukemia patient with a GFR of 43 ml/min; would receive; only 50 % of the curatively scheduled dose in Germany compared States)

This document id is 30170052 .
1.00: (This document id; is; 30170052)

A timely regulatory reassessment of this issue is therefore of great clinical oncological interest .
0.98: (A timely regulatory reassessment of this issue; is therefore; of great clinical oncological interest)

This document id is 30180001 .
1.00: (This document id; is; 30180001)

Vancomycin ( VAN ) is an established treatment option for infections involving methicillin-resistant Staphylococcus aureus strains ( MRSA ) .
1.00: (Vancomycin; is; an established treatment option for infections)
1.00: (infections; involving; methicillin-resistant Staphylococcus aureus strains)

This document id is 30180002 .
1.00: (This document id; is; 30180002)

Vancomycin ( VAN ) is an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains .
1.00: (Vancomycin; is; an established therapeutic option for infections with methicillin-resistant Staphylococcus aureus ( MRSA ) strains)

This document id is 30180011 .
1.00: (This document id; is; 30180011)

However , the bactericidal effect of VAN on MRSA is reduced in strains with minimal inhibitory concentrations ( MICs ) of ≥ 1 mg/L . Due to an apparent correlation of VAN MICs with the risk of treatment failure , both EUCAST and CLSI reduced the `` sensitive '' MIC range to < 2 mg/L . Conversely , the clinical medical societies increased the target ranges of VAN plasma through levels .
0.06: (the bactericidal effect of VAN on MRSA both; is reduced; strains inhibitory ( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure the `` range to < through levels)
0.14: (both EUCAST Conversely the clinical medical societies; reduced increased; the `` sensitive '' MIC range to < 2 mg/L the target ranges of VAN plasma)
0.20: (. the clinical medical societies the target; ranges; of VAN plasma through levels)
0.33: (the target; increased; of VAN plasma through levels)
0.14: (the bactericidal effect of VAN on MRSA societies; is reduced; ( MICs ) of ≥ 1 mg/L Due to an apparent correlation of VAN MICs with the risk of treatment failure VAN plasma through levels)
0.25: (both CLSI Conversely the clinical medical societies; reduced increased; the `` sensitive '' MIC range to < 2 mg/L the target ranges of)
0.24: (mg/L the target; increased; of VAN plasma through levels)

This document id is 30180012 .
1.00: (This document id; is; 30180012)

However , the bactericidal effect of VAN on MRSA is already reduced for strains against which the MIC of VAN increases to ≥1 mg/l . Therefore , because there is a correlation between the MIC and the risk of treatment failure of VAN , EUCAST and CLSI reduced the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l , and clinical societies increased the target ranges for plasma levels .
0.90: (the bactericidal effect of VAN on MRSA; is reduced; for strains already)
0.95: (the MIC of VAN; increases; to ≥1 mg/l)
0.28: (CLSI; reduced; the MIC above which an MRSA strain is considered vancomycin-sensitive to < 2 mg/l)
0.00: (clinical societies; increased; the target ranges for plasma levels)
0.95: (the target; ranges; for plasma levels)
0.95: (strains the MIC of VAN; increases; to ≥1 mg/l)
0.04: (EUCAST; is a correlation between the MIC and the risk of treatment failure of; )

This document id is 30180021 .
1.00: (This document id; is; 30180021)

However , nephrotoxic and ototoxic effects limit the use of increased VAN dosages for the improvement of treatment efficacy .
1.00: (nephrotoxic effects; limit; the use of increased VAN dosages for the improvement of treatment efficacy)
1.00: (ototoxic effects; limit; the use of increased VAN dosages for the improvement of treatment efficacy)

This document id is 30180022 .
1.00: (This document id; is; 30180022)

However , nephro- and ototoxic effects limit VAN dose increases to improve therapy .
0.98: (nephro- effects; limit; VAN dose increases to improve therapy)
0.99: (ototoxic effects; limit; VAN dose increases to improve therapy)

This document id is 30180031 .
1.00: (This document id; is; 30180031)

Trough level monitoring and corresponding dose adjustments are recommended for the optimization of VAN exposure .
1.00: (Trough level monitoring; are recommended; for the optimization of VAN exposure)
1.00: (corresponding dose adjustments; are recommended; for the optimization of VAN exposure)

This document id is 30180032 .
1.00: (This document id; is; 30180032)

Valley level measurements after therapy initiation , with dose adjustment if necessary , are recommended to optimize VAN exposure .
0.99: (Valley level measurements after therapy initiation , with dose adjustment necessary; are recommended; to optimize VAN exposure)
0.00: (Valley level measurements after therapy initiation , with dose adjustment if necessary; to optimize; VAN exposure)

This document id is 30180041 .
1.00: (This document id; is; 30180041)

Using the data of 1122 patients from the years 1990 to 2011 , we investigated the impact of dose regimens and patient characteristics on the attainment of the newly defined target ranges until day 3 and later in the course of treatment .
0.81: (we; investigated; the impact of dose regimens on the attainment of the newly defined target ranges until day 3)
0.99: (the impact of dose regimens on the attainment of the newly defined target; ranges; until day 3)
1.00: (we; investigated; the impact of dose regimens on the attainment of the newly defined target)
0.90: (the impact of dose regimens on the attainment of the newly defined target; ranges; later in the course of treatment)
0.94: (we; investigated; the impact of patient characteristics on the attainment of the newly defined target ranges until day 3)
0.96: (the impact of patient characteristics on the attainment of the newly defined target; ranges; until day 3)
0.93: (we; investigated; the impact of patient characteristics on the attainment of the newly defined target ranges)
0.75: (the impact of patient characteristics on the attainment of the newly defined target; ranges; later in the course of treatment)

This document id is 30180042 .
1.00: (This document id; is; 30180042)

Using data from 1122 patients from 1990 to 2011 , we retrospectively examined the influences of dosing regimens and patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3 and later .
0.71: (we; retrospectively examined; the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by)
0.65: (the influences of dosing regimens on the achievability of newly defined target; ranges; for VAN valley levels therapy day 3 by)
0.51: (we; retrospectively examined; the influences of dosing regimens on the achievability of newly defined target ranges for VAN valley levels by therapy day later)
0.73: (the influences of dosing regimens on the achievability of newly defined target; ranges; for VAN valley levels by therapy day later)
0.70: (we; retrospectively examined; the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day 3)
0.67: (the influences of patient characteristics on the achievability of newly defined target; ranges; for VAN valley levels by therapy day 3)
0.81: (we; retrospectively examined; the influences of patient characteristics on the achievability of newly defined target ranges for VAN valley levels by therapy day later)
0.78: (the influences of patient characteristics on the achievability of newly defined target; ranges; for VAN valley levels by therapy day later)

This document id is 30180051 .
1.00: (This document id; is; 30180051)

With dosages recommended by the manufacturers , the mean trough levels remained clearly below the values recommended by current therapeutic guidelines ( 15–20 mg/L for severe infections ) , particularly in patients without renal impairment .
1.00: (dosages; recommended; by the manufacturers)
0.99: (the mean trough levels; remained clearly; below the values)
1.00: (the values; recommended; by current therapeutic guidelines)

This document id is 30180052 .
1.00: (This document id; is; 30180052)

When dosed according to manufacturer 's instructions , mean valley levels were significantly below the current guideline recommendation ( 15-20 mg/l for severe infections ) , particularly in renally healthy patients .
0.97: (mean valley levels; were; significantly below the current guideline recommendation When dosed according to manufacturer 's instructions)

This document id is 30180061 .
1.00: (This document id; is; 30180061)

Even with body-weight adjusted dosages , only a minority of patients reached plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three .
0.99: (only a minority of patients; reached; plasma levels that meet the guideline recommendations , particularly during the early phase of treatment until day three Even with body-weight adjusted dosages)
0.18: (plasma levels; meet; the guideline recommendations , particularly during the early phase of treatment until day three)

This document id is 30180062 .
1.00: (This document id; is; 30180062)

Even with body-weight-based dosing , only a minority of patients achieved valley levels in line with recommendations , especially by therapy day 3 .
0.80: (only a minority of patients; achieved; valley levels Even with body-weight-based dosing in line with recommendations , especially by therapy day 3)

This document id is 30180071 .
1.00: (This document id; is; 30180071)

A moderate correlation was observed between VAN trough levels and body weight-adjusted dosage .
1.00: (A moderate correlation; was observed; between VAN trough levels and body weight-adjusted dosage)

This document id is 30180072 .
1.00: (This document id; is; 30180072)

There was a moderate correlation of valley level with body-weight-based dosing .
0.94: (a moderate correlation; of; valley level with body-weight-based dosing)

This document id is 30180081 .
1.00: (This document id; is; 30180081)

The intraindividual variability of renal function which is commonly observed in intensive care patients further confounds the predictability of VAN exposure .
1.00: (renal function; is commonly observed; in intensive care patients)
1.00: (The intraindividual variability of renal function; confounds; the predictability of VAN exposure)

This document id is 30180082 .
1.00: (This document id; is; 30180082)

In ICU patients , more frequent fluctuations in renal function have unpredictable effects on VAN exposure .
1.00: (more frequent fluctuations in renal function; have; unpredictable effects on VAN exposure In ICU patients)

This document id is 30180091 .
1.00: (This document id; is; 30180091)

In most cases , VAN dosages beyond the manufacturer recommendation are required to reach the target trough levels specified by the guidelines ( 10–20 mg/L ) .
0.98: (VAN dosages beyond the manufacturer recommendation; are required; to reach the target trough levels In most cases)
0.01: (VAN dosages beyond the manufacturer recommendation; to reach; the target trough levels specified by the guidelines)
0.99: (the target trough levels; specified; by the guidelines)

This document id is 30180092 .
1.00: (This document id; is; 30180092)

In most cases , VAN doses above the manufacturer 's recommendation are needed to achieve the current valley level target ranges of 10 to 20 mg/l . The results argue for early , repeated valley level measurements even in renally healthy patients .
0.46: (VAN doses above the manufacturer 's recommendation; are needed achieve; to the current valley level target of to results In most cases)
0.06: (doses above current valley level . The results; ranges argue; 10 to 20 mg/l for early , repeated valley level measurements even in renally healthy patients)
0.10: (VAN doses above the manufacturer 's recommendation; are needed; In most cases to achieve the current valley level target of 10 to)
0.32: (mg/l The results; ranges; )

This document id is 30180101 .
1.00: (This document id; is; 30180101)

These results strongly support early and repeated VAN trough level measurements even in patients with normal renal function .
0.82: (These results; strongly support; early VAN trough level measurements in patients with normal function even renal)
0.61: (early VAN; trough; level measurements even in patients with normal renal function)
0.90: (These results; strongly support; repeated VAN trough level measurements even in patients with normal renal function)

This document id is 30180102 .
1.00: (This document id; is; 30180102)

The low exposure in the critical early phase and the limited correlation of dosage and exposure suggest the use of other MRSA-active drugs , at least in critically ill patients with infections of organs or deep tissue areas and in nonsusceptible pathogens ( MIC of VAN ≥2 mg/l ) .
1.00: (The low exposure in the critical early phase; suggest; the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens)
1.00: (The low exposure in the critical early phase; suggest; the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens)
1.00: (the limited correlation of dosage; suggest; the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens)
0.99: (the limited correlation of exposure; suggest; the use of other MRSA-active drugs , at least in critically ill patients with infections of organs and in nonsusceptible pathogens)
1.00: (the limited correlation of dosage; suggest; the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens)
1.00: (the limited correlation of exposure; suggest; the use of other MRSA-active drugs , at least in critically ill patients with infections of deep tissue areas and in nonsusceptible pathogens)

This document id is 30180111 .
1.00: (This document id; is; 30180111)

Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
1.00: (the generally low exposure; observed; in the critical early phase)
1.00: (VAN MIC; ≥; 2 mg/L)
0.14: (the generally low exposure observed in the critical early phase; suggest; the use of other antibiotics active against MRSA)

Moreover , the generally low exposure observed in the critical early phase and the limited correlation of dosage and exposure suggest the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs or deep tissues , or if insensitive bacterial strains are involved ( VAN MIC ≥ 2 mg/L ) .
1.00: (the limited correlation of dosage; suggest; the use of other antibiotics active against MRSA)
0.80: (bacterial strains VAN MIC; ≥; 2 mg/L)
0.93: (the limited correlation of exposure; suggest at; the use of other antibiotics active against MRSA)
0.99: (VAN MIC; ≥; 2 mg/L)
1.00: (the generally low exposure; observed; in the critical early phase)
1.00: (the generally low exposure observed in the critical early phase; suggest; the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs)
1.00: (the generally low exposure observed in the critical early phase; suggest; the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues)
1.00: (the limited correlation of dosage; suggest; the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs)
1.00: (the limited correlation of dosage; suggest; the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues)
1.00: (the limited correlation of exposure; suggest; the use of other antibiotics active against MRSA at least in severely ill patients with infections of organs)
1.00: (the limited correlation of exposure; suggest; the use of other antibiotics active against MRSA at least in severely ill patients with infections of deep tissues)

This document id is 30180112 .
1.00: (This document id; is; 30180112)

However , the clinical and microbiological response and the occurrence of toxicity have not been studied .
1.00: (the occurrence of toxicity; have not been studied; )
1.00: (the clinical response; have not been studied; )
1.00: (the microbiological response; have not been studied; )

This document id is 30180121 .
1.00: (This document id; is; 30180121)

Clinical and microbiological responses as well as toxicities were not investigated in this study .
1.00: (Clinical responses as well as toxicities; were not investigated; in this study)
1.00: (microbiological responses as well as toxicities; were not investigated; in this study)

This document id is 30190001 .
1.00: (This document id; is; 30190001)

Meropenem , piperacillin and ceftazidime are commonly used broad spectrum beta-lactam antibiotics in intensive care units .
0.94: (Meropenem; are commonly used; broad spectrum beta-lactam antibiotics in intensive care units)
0.98: (piperacillin; are commonly used; broad spectrum beta-lactam antibiotics in intensive care units)
0.99: (ceftazidime; are commonly used; broad spectrum beta-lactam antibiotics in intensive care units)

This document id is 30190002 .
1.00: (This document id; is; 30190002)

The beta-lactam antibiotics meropenem , piperacillin , and ceftazidime are used in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity .
1.00: (The beta-lactam antibiotics meropenem; are used; in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity)
1.00: (The beta-lactam antibiotics piperacillin; are used; in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity)
0.99: (The beta-lactam antibiotics ceftazidime; are used; in intensive care for the treatment of life-threatening bacterial infectious diseases due to their broad spectrum of activity)

This document id is 30190011 .
1.00: (This document id; is; 30190011)

To improve the therapeutic outcome of the antimicrobial therapy of critically ill patients therapeutic drug monitoring is recommended .
0.99: (To improve the therapeutic outcome of the antimicrobial therapy of critically ill patients therapeutic drug monitoring; is recommended; )

This document id is 30190012 .
1.00: (This document id; is; 30190012)

Due to strong inter- and intraindividual variations in pharmacokinetics , the establishment of therapeutic drug monitoring is recommended to improve therapeutic outcome .
1.00: (the establishment of therapeutic drug monitoring; is recommended; to improve therapeutic outcome)
0.96: (the establishment of therapeutic drug monitoring; to improve; therapeutic outcome)

This document id is 30190021 .
1.00: (This document id; is; 30190021)

Therefore an analytical method was established measuring fluctuating serum levels during therapy .
1.00: (an analytical method; was established; measuring fluctuating serum levels during therapy)
0.99: (an analytical method; measuring; fluctuating serum levels during therapy)

This document id is 30190022 .
1.00: (This document id; is; 30190022)

In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .
1.00: (an analytical HPLC method; is described; In the following)
0.75: (which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml; can be determined quickly; )

In the following , an analytical HPLC method is described , with the help of which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml can be determined quickly and reliably .
1.00: (an analytical HPLC method; is described; In the following)
0.53: (which the serum concentrations of the three beta-lactams in the therapy-relevant range of 2.5 µg/ml ( piperacillin : 6 µg/ml ) to 200 µg/ml; can be determined reliably; )

This document id is 30190031 .
1.00: (This document id; is; 30190031)

A simple and sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection ( DAD ) was developed and validated for simultaneous quantification of these antimicrobial agents .
1.00: (A simple high-performance liquid chromatography ( HPLC ) method with diode array detection; was developed; for simultaneous quantification of these antimicrobial agents)
1.00: (A simple high-performance liquid chromatography ( HPLC ) method with diode array detection; was validated; for simultaneous quantification of these antimicrobial agents)
1.00: (A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection; was developed; for simultaneous quantification of these antimicrobial agents)
1.00: (A sensitive high-performance liquid chromatography ( HPLC ) method with diode array detection; was validated; for simultaneous quantification of these antimicrobial agents)

This document id is 30190032 .
1.00: (This document id; is; 30190032)

The serum levels determined can then be used as a valid basis for further therapy decisions .
1.00: (The serum levels; determined; )
1.00: (The serum levels determined; can be used; as a valid basis for further therapy decisions then)

This document id is 30190041 .
1.00: (This document id; is; 30190041)

For sample preparation a sample amount of 250 µl serum was spiked with cefotaxime as an internal standard .
1.00: (a sample amount of 250 µl serum; was spiked; with cefotaxime as an internal standard For sample preparation)

This document id is 30190051 .
1.00: (This document id; is; 30190051)

Afterwards protein was precipitated using acetonitrile/methanol ( 1:1 ) .
0.99: (protein; was precipitated; Afterwards)

This document id is 30190061 .
1.00: (This document id; is; 30190061)

The supernatant was transferred to HPLC .
1.00: (The supernatant; was transferred; to HPLC)

This document id is 30190071 .
1.00: (This document id; is; 30190071)

A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile and a pH 2.2 phosphoric acid solution was used for separation .
0.99: (A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a gradient of acetonitrile; was used; for separation)
0.99: (A Merck LiChrospher® 100 RP-18 ( 5 µm ) x 125 mm analytical column with a pH 2.2 phosphoric acid solution; was used; for separation)

This document id is 30190081 .
1.00: (This document id; is; 30190081)

Peaks of interest were detected via ultraviolet absorbance at 240 , 298 and 310 nm respectively .
0.98: (Peaks of interest; were detected respectively; at 240 nm)
0.98: (Peaks of interest; were detected respectively; at 298 nm)
0.98: (Peaks of interest; were detected respectively; at 310 nm)

This document id is 30190091 .
1.00: (This document id; is; 30190091)

The method developed shows a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml for each antibiotic in the serum samples .
1.00: (The method; developed; )
0.61: (The method developed; shows; a linear correlation between concentration and response over a concentration range of 2.5 ( piperacillin : 6 ) to 200 µg/ml)

This document id is 30190101 .
1.00: (This document id; is; 30190101)

Validation has demonstrated the method to be accurate and precise too .
1.00: (Validation; has demonstrated; the method to be accurate too)
0.99: (the method; to be too; accurate)
1.00: (Validation; has demonstrated; the method to be precise too)
1.00: (the method; to be too; precise)

This document id is 30190111 .
1.00: (This document id; is; 30190111)

No interferences with other common drugs except metamizole ( dipyrone ) and ceftazidime were detected .
0.99: (No interferences with other common drugs except metamizole; were detected; )
1.00: (No interferences with other common drugs except ceftazidime; were detected; )

This document id is 30190121 .
1.00: (This document id; is; 30190121)

The method is currently used in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients .
1.00: (The method; is used; in the pharmacy department of the German Army Hospital in Berlin for therapeutic drug monitoring ( TDM ) of beta-lactams in critically ill patients currently)

This document id is 30200001 .
1.00: (This document id; is; 30200001)

The frequency of bacterial infections for which antibiotics no longer work is increasing worldwide due to the development of antibiotic resistance among pathogens .
1.00: (The frequency of bacterial infections; is increasing; worldwide due to the development of antibiotic resistance among pathogens)

This document id is 30200002 .
1.00: (This document id; is; 30200002)

The frequency of bacterial infections for which antibiotics are no longer effective is increasing worldwide due to the development of resistance in pathogens .
0.96: (bacterial infections; are; antibiotics no longer effective)
0.08: (The frequency of bacterial infections; is increasing; worldwide due to the development of resistance in pathogens)

This document id is 30200011 .
1.00: (This document id; is; 30200011)

Research topics , in order to counter this threat , include the development of new antibiotics , the reactivation of existing antibacterial agents and the finding of resistance-modifying properties of natural substances .
0.98: (Research topics , in order; include; the development of new antibiotics)
0.97: (Research topics , in order; include; the reactivation of existing antibacterial agents)
0.98: (Research topics , in order; include; the finding of resistance-modifying properties of natural substances)

This document id is 30200012 .
1.00: (This document id; is; 30200012)

To counter this threat , research is being conducted - in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products .
0.89: (research; is being conducted; To counter this threat in addition to the development of new antibiotics and the reactivation of existing antibacterial agents - into the resistance-modifying properties of natural products)

This document id is 30200021 .
1.00: (This document id; is; 30200021)

In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) and an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae .
0.99: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work)
0.75: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) with lysozyme amplify the effects of a carbapenem- ( ) against the bacterial pathogens)
0.63: (from cloves; combined; how the essential oils ( Syzygium aromaticum ) with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Pseudomonas aeruginosa)
0.69: (the essential oils from cloves combined with lysozyme; amplify; the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Pseudomonas aeruginosa)
0.75: (the bacterial pathogens; Pseudomonas aeruginosa; )
0.94: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae In the present work)
0.72: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens pneumoniae)
0.63: (the essential oils from cloves; combined; how ( Syzygium aromaticum ) with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae)
0.73: (the essential oils from cloves combined with lysozyme; amplify; the effects of a carbapenem- ( imipenem bacterial pathogens Klebsiella pneumoniae)
0.61: () against the bacterial pathogens; Klebsiella pneumoniae; )
1.00: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens In the present work)
0.86: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens)
0.63: (the essential oils from cloves; combined; how ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa)
0.85: (the essential oils from cloves combined with lysozyme; amplify; the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa)
0.94: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae In the present work)
0.78: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae)
0.64: (essential oils from cloves; combined; how the ( Syzygium aromaticum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae)
0.88: (the essential oils from cloves combined with lysozyme; amplify; the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae)
0.79: (the bacterial pathogens; Klebsiella pneumoniae; )
1.00: (the checkerboard microdilution method; was used; to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens In the present work)
0.55: (the checkerboard microdilution method; to investigate; the essential oils from cinnamon ) with lysozyme a ) against the bacterial pathogens Pseudomonas aeruginosa)
0.90: (the essential oils from cinnamon combined with lysozyme; amplify; the effects of a carbapenem- imipenem)
0.71: (( ) against the bacterial pathogens; Pseudomonas aeruginosa; )
0.93: (the checkerboard microdilution method; was used; to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae In the present work)
0.55: (the checkerboard microdilution method; to investigate; the essential oils from cinnamon ) with lysozyme effects a ) against the bacterial pathogens Klebsiella pneumoniae)
0.45: (the checkerboard microdilution method; investigate; how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of a carbapenem- ( imipenem ) against the bacterial pathogens Klebsiella pneumoniae)
0.96: (the essential oils from cinnamon combined with lysozyme; amplify; the effects of a carbapenem-)
1.00: (the checkerboard microdilution method; was used; to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens In the present work)
0.84: (the checkerboard microdilution method; to investigate; how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens aeruginosa)
0.77: (the essential oils from cinnamon ( Cinnamomum verum ); combined; how with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa)
0.91: (the essential oils from cinnamon combined with lysozyme; amplify; the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Pseudomonas aeruginosa)
0.85: (bacterial pathogens; Pseudomonas aeruginosa; )
0.98: (the checkerboard microdilution method; was used; to investigate how the essential oils from cinnamon ( Cinnamomum verum ) combined with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae In the present work)
0.67: (the checkerboard microdilution method; to investigate; how the essential oils from cinnamon ( Cinnamomum verum ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae)
0.42: (the checkerboard microdilution method ( Cinnamomum verum; combined; how the essential oils from cinnamon ) with lysozyme amplify the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae)
0.92: (the essential oils from cinnamon combined with lysozyme; amplify; the effects of an aminoglycoside-antibiotic ( gentamicin ) against the bacterial pathogens Klebsiella pneumoniae)
0.67: () the bacterial pathogens; pneumoniae; Klebsiella)

This document id is 30200022 .
1.00: (This document id; is; 30200022)

In the present work , the checkerboard microdilution method was used to investigate how the essential oils from cloves ( Syzygium aromaticum ) and the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) and aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa and Klebsiella pneumoniae , respectively .
0.94: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens respectively In the present work)
0.73: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens aeruginosa ,)
0.76: (the essential oils from cloves; combined; how with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.62: (the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme; enhance; the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.91: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work)
0.79: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae respectively)
0.82: (the essential oils from cloves; combined; how with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
0.60: (the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme; enhance; the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
0.95: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens respectively In the present work)
0.65: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa ,)
0.55: (the essential oils from cloves; combined; how ( Syzygium aromaticum ) with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.79: (the essential oils from cloves combined with lysozyme; enhance; the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.48: (bacterial pathogens; Pseudomonas aeruginosa , respectively; )
0.82: (the checkerboard microdilution method; was used; to investigate how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens pneumoniae , respectively In the present work)
0.67: (the checkerboard microdilution method; to investigate; how the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
0.81: (the essential oils from cloves; combined; how with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
0.61: (the essential oils from cloves ( Syzygium aromaticum ) combined with lysozyme; enhance; the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
1.00: (the checkerboard microdilution method; was used; to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens In the present work)
0.77: (the checkerboard microdilution method; to investigate; how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens)
0.52: (the essential oils from the bark of the cinnamon tree; combined; how ( Cinnamomum verum ) with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.59: (the essential oils from the bark of the cinnamon tree combined with; enhance; lysozyme the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.88: (the checkerboard microdilution method; was used; to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens , respectively In the present work)
0.66: (the checkerboard microdilution method; to investigate; how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae respectively)
0.76: (the essential oils from the bark of the cinnamon tree; combined; with lysozyme enhance the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
0.60: (the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme; enhance; the effects of antibiotics from the carbapenems ( imipenem ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
1.00: (the checkerboard microdilution method; was used; to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens In the present work)
0.73: (the checkerboard microdilution method; to investigate; how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens)
0.53: (the essential oils from the bark of the cinnamon tree; combined; how ( Cinnamomum verum ) with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.60: (the essential oils from the bark of the cinnamon tree combined; enhance; with lysozyme the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Pseudomonas aeruginosa , respectively)
0.51: (the checkerboard microdilution method; was used; to investigate how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively In the present work)
0.54: (the checkerboard microdilution method; to investigate; how the essential oils from the bark of the cinnamon tree ( Cinnamomum verum ) combined with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens pneumoniae , respectively)
0.65: (the essential oils from the bark of the cinnamon tree verum ); combined; how with lysozyme enhance the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)
0.64: (the essential oils from the bark of the cinnamon tree ( Cinnamomum combined with lysozyme; enhance; the effects of antibiotics from the aminoglycosides ( gentamicin ) groups against the bacterial pathogens Klebsiella pneumoniae , respectively)

This document id is 30200031 .
1.00: (This document id; is; 30200031)

The results indicate that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin and imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species and thus significantly increase the antibiotic effects .
1.00: (The results; indicate; that the essential oils of both plant species thus significantly increase the antibiotic effects)
0.98: (the essential oils of both plant species; significantly increase; the antibiotic effects)
1.00: (The results; indicate; that the essential oils of both plant species reduce the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species)
1.00: (the essential oils of both plant species; reduce; the minimum inhibitory concentrations of gentamicin against multi-drug resistant clinical isolates of the two gram-negative bacterial species)
1.00: (The results; indicate; that the essential oils of both plant species reduce the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species)
1.00: (the essential oils of both plant species; reduce; the minimum inhibitory concentrations of imipenem against multi-drug resistant clinical isolates of the two gram-negative bacterial species)

This document id is 30200032 .
1.00: (This document id; is; 30200032)

The results show that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin and imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species , thereby significantly enhancing antibiotic efficacy .
1.00: (The results; show; that the essential oils of both plant species decrease the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species)
1.00: (the essential oils of both plant species; decrease; the minimum inhibitory concentrations of gentamicin against multidrug-resistant clinical isolates of the two Gram-negative bacterial species)
0.60: (the essential oils of both plant species; significantly enhancing; antibiotic efficacy)
1.00: (The results; show; that the essential oils of both plant species decrease the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species)
1.00: (the essential oils of both plant species; decrease; the minimum inhibitory concentrations of imipenem against multidrug-resistant clinical isolates of the two Gram-negative bacterial species)

This document id is 30200041 .
1.00: (This document id; is; 30200041)

The observed potent resistance-modifying properties of the essential oils favour further investigations of the phenylpropanoids as the main components of both oils and other natural substances in this context .
1.00: (The observed potent resistance-modifying properties of the essential oils; favour; further investigations of the phenylpropanoids as the main components of both oils in this context)
1.00: (The observed potent resistance-modifying properties of the essential oils; favour; further investigations of the phenylpropanoids as the main components of both other natural substances in this context)

This document id is 30200042 .
1.00: (This document id; is; 30200042)

The potent resistance-modifying properties of the essential oils suggest further investigation of phenylpropanoids as major components of both oils and other natural products in this context is promising .
1.00: (The potent resistance-modifying properties of the essential oils; suggest; further investigation of phenylpropanoids as major components of both oils in this context is promising)
1.00: (further investigation of phenylpropanoids as major components of both oils in this context; is; promising)
0.99: (The potent resistance-modifying properties of the essential oils; suggest; further investigation of phenylpropanoids as major components of both other natural products in this context is promising)
0.99: (further investigation of phenylpropanoids as major components of both other natural products in this context; is; promising)

This document id is 30210001 .
1.00: (This document id; is; 30210001)

Due to lack of reliable therapy and insufficient available vaccines against SARS-CoV-2 , researchers are looking for promising and effective therapy in substances that are already available .
1.00: (researchers; are looking; for promising therapy in substances)
1.00: (substances; are; already available)
1.00: (researchers; are looking; for effective therapy in substances)

This document id is 30210002 .
1.00: (This document id; is; 30210002)

Since there is still no reliable therapy and not enough approved vaccines against SARS-CoV-2 , research is looking for promising , effective substances that are already available .
1.00: (research; is looking; for promising , effective substances)
1.00: (promising , effective substances; are; already available)

This document id is 30210011 .
1.00: (This document id; is; 30210011)

The objective of the current study is to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2 .
0.95: (The objective of the current study; is; to investigate whether the herbal preparation Cystus Pandalis® ( CPE ) has in vitro antiviral properties against SARS-CoV-2)
0.92: (the herbal preparation; has; in vitro antiviral properties)

This document id is 30210012 .
1.00: (This document id; is; 30210012)

This study will investigate whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2 , as it has already been shown to be effective against several other viruses .
0.45: (it; has been shown; effective against other viruses already)
0.76: (it; to be; antiviral properties against SARS-CoV-2 effective against several other viruses)
0.98: (This study; will investigate; whether the herbal preparation Cystus Pandalis® has in vitro antiviral properties against SARS-CoV-2)
0.71: (the herbal preparation; has; in vitro antiviral properties against SARS-CoV-2)

This document id is 30210021 .
1.00: (This document id; is; 30210021)

CPE has already proved to be effective against several other viruses .
0.98: (CPE; has proved; already)
1.00: (CPE; to be; effective against several other viruses)

This document id is 30210022 .
1.00: (This document id; is; 30210022)

At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures were infected with SARS-CoV-2 using Cystus Pandalis® extract ( CPE ) , and the reduction in infection rate was evaluated by comparing foci-forming units .
1.00: (cell cultures; were infected; with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy)
0.92: (cell cultures; using; Cystus Pandalis® extract)
0.87: (the reduction in infection rate; was evaluated; by comparing units At the Fraunhofer Institute for Cell Therapy)
1.00: (the reduction in infection rate; by comparing; foci-forming units)
0.91: (cell cultures; were infected; with SARS-CoV-2 using Cystus Pandalis® At the Fraunhofer Institute for Immunology)
0.88: (the reduction in infection rate; was evaluated; by comparing foci-forming units At the Fraunhofer Institute for Immunology)

This document id is 30210031 .
1.00: (This document id; is; 30210031)

At the Fraunhofer Institute for Cell Therapy and Immunology ( IZI ) , cell cultures treated with Cystus Pandalis® extract were infected with SARS-CoV-2 , and the reduction in the infection rate was evaluated by comparing focus-forming units .
1.00: (cell cultures; treated; with Cystus Pandalis® extract)
0.83: (( IZI ) cell cultures treated with Cystus Pandalis® extract; were infected; with SARS-CoV-2 At the Fraunhofer Institute for Cell Therapy)
0.84: (the reduction in the infection rate; was evaluated; by comparing focus-forming units At the Fraunhofer Institute for Cell Therapy)
0.82: (IZI ) cell cultures treated with Cystus Pandalis® extract; were infected; with SARS-CoV-2 At the Fraunhofer Institute for Immunology)
0.85: (the reduction in the infection rate; was evaluated; by comparing focus-forming units At the Fraunhofer Institute for Immunology)

This document id is 30210032 .
1.00: (This document id; is; 30210032)

An almost complete reduction in infection rate by CPE was observed at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml .
1.00: (An almost complete reduction in infection rate by CPE; was observed; at concentrations greater than 15.6 µg/ml with a calculated EC50 of 1.94 µg/ml)

This document id is 30210041 .
1.00: (This document id; is; 30210041)

An almost complete reduction in the CPE infection rate was observed at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml .
1.00: (An almost complete reduction in the CPE infection rate; was observed; at concentrations of greater than 15.6 µg/ml with a calculated EC50 ( mean effective concentration ) of 1.94 µg/ml)

This document id is 30210042 .
1.00: (This document id; is; 30210042)

The mechanism of action of this extract may be based on the high polymer polyphenols that coat certain viral epitopes , causing CPE to act as an entry inhibitor .
1.00: (The mechanism of action of this extract; may be based; on the high polymer polyphenols)
1.00: (the high polymer polyphenols; coat; certain viral epitopes)
0.37: (the high polymer polyphenols that ,; certain viral epitopes causing; CPE to act as an entry inhibitor)
0.98: (CPE; to act; as an entry inhibitor)

This document id is 30210051 .
1.00: (This document id; is; 30210051)

The mechanism of action of this extract may be based on the highly polymeric polyphenols that envelop certain viral epitopes , whereby CPE acts as an entry inhibitor .
1.00: (The mechanism of action of this extract; may be based; on the highly polymeric polyphenols)
0.98: (the highly polymeric polyphenols; envelop; certain viral epitopes , whereby CPE acts as an entry inhibitor)
1.00: (CPE; acts; as an entry inhibitor)

This document id is 30210052 .
1.00: (This document id; is; 30210052)

Due to the high in vitro activity , it seems reasonable to use CPE as prophylaxis against infections with SARS-CoV-2 .
0.95: (it; to use; CPE as prophylaxis against infections with SARS-CoV-2)

This document id is 30210061 .
1.00: (This document id; is; 30210061)

The high in vitro activity of CPE seems to make it a reasonable candidate for prophylaxis against SARS-CoV-2 .
1.00: (The high in vitro activity of CPE; seems; )
1.00: (The high in vitro activity of CPE; to make; it a reasonable candidate for prophylaxis against SARS-CoV-2)

This document id is 30220001 .
1.00: (This document id; is; 30220001)

Fruits from Apium graveolens ( celery ) are used traditionally in Persian and European medicine for the treatment of uncomplicated urinary tract infections .
0.99: (Fruits from Apium graveolens; are used traditionally; in Persian medicine for the treatment of uncomplicated urinary tract infections)
0.99: (Fruits from Apium graveolens; are used traditionally; in European medicine for the treatment of uncomplicated urinary tract infections)

This document id is 30220002 .
1.00: (This document id; is; 30220002)

The fruits of Apium graveolens L. ( celery ) are used in traditional Persian and European medicine for the treatment of uncomplicated urinary tract infections ( UTI ) .
1.00: (The fruits of Apium graveolens L.; are used; in traditional Persian medicine for the treatment of uncomplicated urinary tract infections)
1.00: (The fruits of Apium graveolens L.; are used; in traditional European medicine for the treatment of uncomplicated urinary tract infections)

This document id is 30220011 .
1.00: (This document id; is; 30220011)

No data are available on A. graveolens extract on the interplay between uropathogenic E. coli and the eukaryotic host cells and on quorum sensing of the bacteria .
0.73: (No data; are; available on A. graveolens on sensing of the bacteria extract quorum)
0.89: (No data; are; available on A. graveolens extract on the interplay between uropathogenic E. coli)
0.89: (No data; are; available on A. graveolens extract on the interplay between the eukaryotic host cells)

This document id is 30220012 .
1.00: (This document id; is; 30220012)

To date , no data are available investigating the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder and kidney and bacterial quorum sensing .
0.94: (no data; are; available investigating corresponding To date)
1.00: (no data; investigating; the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bacterial quorum sensing)
0.75: (no data; are; available investigating influence of corresponding drug extracts with regard to To date)
1.00: (no data; investigating; the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from bladder)
0.74: (no data; are; available investigating influence of corresponding drug extracts with regard To date)
1.00: (no data; investigating; the influence of corresponding drug extracts with regard to adhesion of uropathogenic E. coli to eukaryotic host cells from kidney)

This document id is 30220021 .
1.00: (This document id; is; 30220021)

The present study aimed to characterize an antiadhesive and anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays and to correlate these effects with in vivo data obtained by an animal infection model .
0.77: (The present study; aimed to; correlate these effects with in vivo data)
0.13: (The present study in vivo data; correlate obtained; these effects with by an animal infection model)
0.99: (The present study; aimed; to characterize an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays)
0.99: (The present study; aimed to characterize; an antiadhesive effect of a characterized A. graveolens extract by specific in vitro assays)
0.85: (The present study; aimed; to characterize an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays)
0.99: (The present study; aimed to characterize; an anti quorum sensing effect of a characterized A. graveolens extract by specific in vitro assays)

This document id is 30220022 .
1.00: (This document id; is; 30220022)

The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
1.00: (The present studies; describe; a marked anti-adhesive effect of an extract of A. graveolens)
1.00: (A. graveolens; using; in vitro studies)

The present studies describe a marked anti-adhesive and anti-quorum sensing effect of an extract of A. graveolens using in vitro studies and in vivo studies in the mouse infection model .
1.00: (The present studies; describe; a marked anti-adhesive effect of an extract of A. graveolens)
0.89: (A. graveolens; using; in vivo studies in the mouse infection model)
1.00: (The present studies; describe; a marked anti-quorum sensing effect of an extract of A. graveolens)
0.29: (A. graveolens; sensing using; in vivo studies in the mouse infection model)

This document id is 30220031 .
1.00: (This document id; is; 30220031)

Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits was characterized by UHPLC/+ESI-QTOF-MS and investigated on antiproliferative activity against UPEC ( strain NU14 ) and human T24 bladder cells .
1.00: (Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits; was characterized; by UHPLC/+ESI-QTOF-MS)
1.00: (Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits; was investigated; on antiproliferative activity against UPEC)
1.00: (Hydroalcoholic extract CSE ( EtOH-water , 1:1 ) from A. graveolens fruits; was investigated; on antiproliferative activity against human T24 bladder cells)

This document id is 30220032 .
1.00: (This document id; is; 30220032)

A hydroalcoholic extract ( Cellery Seed Extract , CSE ; EtOH-water , 1:1 ) of A. graveolens fruit was phytochemically characterized by UHPLC/+ESI-QTOF-MS and evaluated for antiproliferative properties against UPEC ( strain NU14 ) and human T24 blast cells .
0.89: (A hydroalcoholic extract EtOH-water , 1:1 ) of A. graveolens fruit; was phytochemically characterized; by UHPLC/+ESI-QTOF-MS)
0.82: (extract EtOH-water , 1:1 ) of A. graveolens fruit; was evaluated; for antiproliferative properties against UPEC ( strain)
0.95: (extract ; EtOH-water , 1:1 ) of A. graveolens fruit; was evaluated; for antiproliferative properties against human T24 blast cells)

This document id is 30220041 .
1.00: (This document id; is; 30220041)

Antiadhesive properties of CSE were investigated within two different in vitro adhesion assays .
1.00: (Antiadhesive properties of CSE; were investigated; within two different in vitro adhesion assays)

This document id is 30220042 .
1.00: (This document id; is; 30220042)

Anti-adhesive effects of CSE were tested by two in vitro adhesion assays .
1.00: (Anti-adhesive effects of CSE; were tested; by two in vitro adhesion assays)

This document id is 30220051 .
1.00: (This document id; is; 30220051)

For in vivo studies BALB/c mice were used in an UPEC infection model .
1.00: (BALB/c mice; were used; in an UPEC infection model For in vivo studies)

This document id is 30220052 .
1.00: (This document id; is; 30220052)

For in vivo studies , BALB/c mice were used in a UPEC infection model and the effect of CSE on bacterial load in bladder and kidney tissues was investigated in the context of 4- and 7-day pretreatment ( 200 , 500 mg/kg ) , respectively .
1.00: (BALB/c mice; were used; in a UPEC infection model For in vivo studies)
0.89: (the effect of CSE on bacterial load in bladder tissues; was investigated respectively; in the context of 4- pretreatment For in vivo studies)
0.85: (the effect of CSE on bacterial load in bladder tissues; was investigated respectively; in the context of 7-day pretreatment For in vivo studies)
0.89: (the effect of CSE on bacterial load in kidney tissues; was investigated respectively; in the context of 4- pretreatment For in vivo studies)
1.00: (the effect of CSE on bacterial load in kidney tissues; was investigated; in the context of 7-day pretreatment For in vivo studies)

This document id is 30220061 .
1.00: (This document id; is; 30220061)

The effect of CSE on bacterial load in bladder tissue was monitored within a 4- and 7 days pretreatment ( 200 , 500 mg/kg ) of the animals .
1.00: (The effect of CSE on bacterial load in bladder tissue; was monitored; within a 4- days pretreatment)
0.88: (The effect of CSE on bacterial load in bladder tissue; was monitored; within a 7 days pretreatment the)

This document id is 30220062 .
1.00: (This document id; is; 30220062)

CSE is phytochemically characterized by the presence of luteolin glycosides , similar flavones , and furanocoumarins .
1.00: (CSE; is phytochemically characterized; by the presence of luteolin glycosides)
1.00: (CSE; is phytochemically characterized; by the presence of similar flavones)
1.00: (CSE; is phytochemically characterized; by the presence of furanocoumarins)

This document id is 30220071 .
1.00: (This document id; is; 30220071)

CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .
1.00: (CSE; was dominated; by the presence of luteolin-glycosides besides furocoumarins)

CSE was dominated by the presence of luteolin-glycosides and related flavones besides furocoumarins .
1.00: (CSE; was dominated; by the presence of related flavones besides furocoumarins)

This document id is 30220072 .
1.00: (This document id; is; 30220072)

CSE shows no cytotoxic effects against UPEC and blast cells , but exhibits concentration-dependent antiadhesive effects against UPEC strain NU14 and UTI89 .
1.00: (CSE; shows; no cytotoxic effects against UPEC)
1.00: (CSE; shows; no cytotoxic effects against blast cells)
0.99: (CSE; exhibits; concentration-dependent antiadhesive effects against UPEC strain)
1.00: (CSE; exhibits; concentration-dependent antiadhesive effects against UTI89)

This document id is 30220081 .
1.00: (This document id; is; 30220081)

CSE had no cytotoxic effects against UPEC and bladder cells .
1.00: (CSE; had; no cytotoxic effects against UPEC)
1.00: (CSE; had; no cytotoxic effects against bladder cells)

This document id is 30220082 .
1.00: (This document id; is; 30220082)

CSE inhibits bacterial quorum sensing in a concentration-dependent manner .
1.00: (CSE; inhibits; bacterial quorum sensing in a concentration-dependent manner)

This document id is 30220091 .
1.00: (This document id; is; 30220091)

CSE exerts a dose dependent antiadhesive activity against UPEC strains NU14 and UTI89 .
1.00: (CSE; exerts; a dose dependent antiadhesive activity against UPEC)
0.78: (a dose dependent antiadhesive activity against UPEC; strains; NU14)
0.80: (a dose dependent antiadhesive activity against UPEC; strains; UTI89)

This document id is 30220092 .
1.00: (This document id; is; 30220092)

In vivo 4 and 7 day pretreatment of mice with CSE followed by transurethal UPEC NU14 infection significantly inhibited bacterial load in bladder tissue .
0.75: (4 day pretreatment of mice with CSE; followed; by transurethal UPEC NU14 infection)
0.29: (In vivo 4 day pretreatment of mice with CSE; significantly inhibited; bacterial load in bladder tissue)
0.77: (7 day pretreatment of mice with CSE; followed; by transurethal UPEC NU14 infection)
0.28: (In vivo 7 day pretreatment of mice with CSE; significantly inhibited; bacterial load in bladder tissue)

This document id is 30220101 .
1.00: (This document id; is; 30220101)

CSE inhibited in a concentration-dependent manner bacterial quorum sensing .
0.99: (CSE; inhibited; in a concentration-dependent manner)
0.77: (a concentration-dependent manner bacterial quorum; sensing; )

This document id is 30220102 .
1.00: (This document id; is; 30220102)

Based on these data , the traditional use of the drug in UTI appears to be justified .
1.00: (the traditional use of the drug in UTI; appears; )
1.00: (the traditional use of the drug in UTI; to be justified; )

This document id is 30220111 .
1.00: (This document id; is; 30220111)

4- and 7-day pretreatment of animals with CSE transurethrally infected with UPEC NU14 , significantly reduced the bacterial load in bladder tissue .
1.00: (CSE; transurethrally infected; with UPEC NU14)
0.99: (4- pretreatment of animals with CSE; significantly reduced; the bacterial load in bladder tissue)
0.98: (7-day pretreatment of animals with CSE; significantly reduced; the bacterial load in bladder tissue)

This document id is 30220121 .
1.00: (This document id; is; 30220121)

CSE is assessed as an antiadhesive extract for which the traditional use in phytotherapy for UTI is justified .
1.00: (CSE; is assessed; as an antiadhesive extract)
0.94: (an antiadhesive extract; is justified; the traditional use in phytotherapy for UTI)

This document id is 30230001 .
1.00: (This document id; is; 30230001)

2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate product for the two step-synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant .
0.79: (2- ( 4-Chlorophenyl ) -4-metathiazanone; is; the intermediate product for the two step-synthesis of chlormezanone ()

This document id is 30230002 .
1.00: (This document id; is; 30230002)

2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2 ) is the intermediate in the two-step synthesis of chlormezanone ( 1 ) , a centrally acting muscle relaxant .
0.92: (2- ( 4-Chlorophenyl ) -4-metathiazanone ( 2; is; the intermediate in the two-step synthesis of chlormezanone ()

This document id is 30230011 .
1.00: (This document id; is; 30230011)

The second step includes the oxidation of its sulfur atom .
1.00: (The second step; includes; the oxidation of its sulfur atom)

This document id is 30230012 .
1.00: (This document id; is; 30230012)

The second step is the oxidation of the sulfur atom .
1.00: (The second step; is; the oxidation of the sulfur atom)

This document id is 30230021 .
1.00: (This document id; is; 30230021)

It has been found that the foregoing reaction of 4-chlorobenzaldehyde with methylamine forming the hemiaminale and the subsequent addition of β-mercaptopropionic acid leads to a remarkable better yield ( 67 % of th . )
1.00: (methylamine; forming; the hemiaminale)
0.81: (It; has been found; )
0.98: (the foregoing reaction of 4-chlorobenzaldehyde with methylamine; leads; to a remarkable better yield)
1.00: (the subsequent addition of β-mercaptopropionic acid; leads; to a remarkable better yield)

This document id is 30230022 .
1.00: (This document id; is; 30230022)

A much improved yield ( 67 % d.th . )

This document id is 30230031 .
1.00: (This document id; is; 30230031)

than the route via the hemimercaptale ( 42 % of th . ) .2 could be oxidized with sodium perborate superior to potassium permanganate .
0.79: (the route via ( 42 % of th . ) .2; could be oxidized; with sodium perborate superior to potassium permanganate hemimercaptale)

This document id is 30230032 .
1.00: (This document id; is; 30230032)

of 2 is obtained when the half-aminal is first formed from 4-chlorobenzaldehyde and methylamine , which then reacts with β-mercaptopropionic acid , than when the reverse is added via the half-mercaptal ( 42 % d.th . ) .
0.88: (of 2; is obtained; when the half-aminal is first formed from 4-chlorobenzaldehyde , then acid)
1.00: (the half-aminal; is formed; from 4-chlorobenzaldehyde first)
1.00: (4-chlorobenzaldehyde; reacts; with β-mercaptopropionic acid then)
1.00: (the reverse; is added; )
0.94: (of 2; is obtained; when the half-aminal is first formed from methylamine , which then reacts with β-mercaptopropionic acid)
1.00: (the half-aminal; is formed; from methylamine first)
1.00: (methylamine; reacts; with β-mercaptopropionic acid then)
0.36: (the reverse; is added; via the half-mercaptal d.th)

This document id is 30230041 .
1.00: (This document id; is; 30230041)

The racemic chlormezanone ( 1 ) is resolved quickly on a gram scale by preparative column chromatography on a Chiralcel® OD column ( tris ( 3,5-dimethyl-phenyl-carbamoyl ) cellulose on silicagel ) .
1.00: (The racemic chlormezanone; is resolved quickly; on a gram scale by preparative column chromatography on a Chiralcel® OD column)

This document id is 30230042 .
1.00: (This document id; is; 30230042)

Sodium perborate is clearly superior to potassium permanganate as an oxidizing agent .
1.00: (Sodium perborate; is; clearly superior to potassium permanganate as an oxidizing agent)
0.56: (Sodium perborate; to; potassium permanganate as an oxidizing agent)

This document id is 30230051 .
1.00: (This document id; is; 30230051)

The resolution needed only 40 min , if flow rate , composition of the mobile phase and temperature as the most important factors are determined prior with an analytical column .
1.00: (The resolution; needed; only 40 min)
0.84: (flow rate; are determined; prior with an analytical column)
0.93: (composition of the mobile phase; are determined; prior with an analytical column)
0.91: (temperature as the most important factors; are determined; prior with an analytical column)

This document id is 30230052 .
1.00: (This document id; is; 30230052)

The racemic chloromezanone ( 1 ) can be separated rapidly in the grammaÞstab on a Chiralcel® OD column .
0.75: (The racemic chloromezanone; can be separated rapidly; in the grammaÞstab on a Chiralcel® column)

This document id is 30230061 .
1.00: (This document id; is; 30230061)

Both dissociation constants could be determined for the first time with the aid of a log pKa-Titrator of the Sirius Co. , which needs for the registration of the curves only 15–17 min in the pH range of 2–12 .
1.00: (Both dissociation constants; could be determined; for the first time with the aid of a log pKa-Titrator of the Sirius Co.)
0.65: (the Sirius Co.; needs; for the registration of the curves only)

This document id is 30230062 .
1.00: (This document id; is; 30230062)

If the crucial factors such as flow rate , mobile phase composition and temperature are first determined on analytical columns , then the separation requires only 40 min .
0.99: (the crucial factors such as flow rate; are determined; on analytical columns first)
1.00: (the separation; requires; only 40 min then)
1.00: (the crucial factors such as mobile phase composition; are determined; on analytical columns first)
1.00: (the crucial factors such as temperature; are determined; on analytical columns first)

This document id is 30230071 .
1.00: (This document id; is; 30230071)

This speed outplayed the disturbing cleavage of the S-C bond of chlormezanone at strong acidic and alkaline pH values .
0.84: (This speed; outplayed; the disturbing cleavage of the S-C bond of chlormezanone at strong acidic pH values)
0.78: (This speed; outplayed; the disturbing cleavage of the S-C bond of chlormezanone at strong alkaline pH values)

This document id is 30230072 .
1.00: (This document id; is; 30230072)

For the first time , the two dissociation constants of 1 could be determined using the log pKa titrator from Sirius Co. which requires only 15-17 min to register the titration curves in the pH range 2-12 .
0.89: (the two dissociation constants of 1; could be determined; For the first time)
0.99: (the log pKa titrator from Sirius Co.; requires; only 15-17 min to register the titration curves in the pH range 2-12)
0.29: (only 15-17 min; to register; the titration curves in the pH range 2-12)

This document id is 30230082 .
1.00: (This document id; is; 30230082)

This speed glosses over the interfering break in the S-C bond of 1 in the strongly acidic and strongly alkaline pH ranges .
0.96: (This speed; glosses; over the interfering break in the S-C bond of 1 in the strongly acidic pH ranges)
0.81: (the interfering break in the S-C bond of 1 in the strongly acidic pH; ranges; )
0.88: (the interfering break in the S-C bond of 1 in the strongly alkaline pH; ranges; )

This document id is 30240001 .
1.00: (This document id; is; 30240001)

Background and objectives : The efficacy and tolerance of an antiseptic wound powder based on the antibiotic tyrothricin was investigated in a prospective , randomized multicenter trial in patients with posttraumatic and surgical cutaneous lesions .
1.00: (an antiseptic wound powder; based; on the antibiotic tyrothricin)
1.00: (The efficacy of an antiseptic wound powder; was investigated; in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions)
1.00: (The efficacy of an antiseptic wound powder; was investigated; in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions)
1.00: (The tolerance of an antiseptic wound powder; was investigated; in a prospective , randomized multicenter trial in patients with posttraumatic cutaneous lesions)
1.00: (The tolerance of an antiseptic wound powder; was investigated; in a prospective , randomized multicenter trial in patients with surgical cutaneous lesions)

This document id is 30240002 .
1.00: (This document id; is; 30240002)

Background and Purpose : In a prospective , randomized multicenter study , the efficacy and tolerability of an antibiotic wound powder containing the active ingredient tyrothricin were investigated in posttraumatic and postoperative skin lesions .
1.00: (an antibiotic wound powder; containing; the active ingredient tyrothricin)
1.00: (the efficacy of an antibiotic wound powder; were investigated; in posttraumatic skin lesions In a prospective , randomized multicenter study)
1.00: (the efficacy of an antibiotic wound powder; were investigated; in postoperative skin lesions In a prospective , randomized multicenter study)
1.00: (the tolerability of an antibiotic wound powder; were investigated; in posttraumatic skin lesions In a prospective , randomized multicenter study)
1.00: (the tolerability of an antibiotic wound powder; were investigated; in postoperative skin lesions In a prospective , randomized multicenter study)
0.99: (an antibiotic wound powder; containing; the active ingredient tyrothricin randomized)
0.14: (the efficacy of an antibiotic wound powder; were investigated; in posttraumatic skin lesions Purpose In a prospective , randomized multicenter study)
0.13: (the efficacy of an antibiotic wound powder; were investigated; in postoperative skin lesions Purpose In a prospective , randomized multicenter study)
0.96: (the tolerability of an antibiotic wound powder; were investigated; in posttraumatic skin lesions Purpose In a prospective , randomized multicenter study)
0.96: (the tolerability of an antibiotic wound powder; were investigated; in postoperative skin lesions Purpose In a prospective , randomized multicenter study)

This document id is 30240011 .
1.00: (This document id; is; 30240011)

Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
0.99: (131 male patients from 18–85 years; were included; with posttraumatic cutaneous lesions with infection In 5 centers)
0.95: (Patients area; ≥; 200 mm2)
0.98: (131 male patients from 18–85 years; were included; with posttraumatic cutaneous lesions in danger of infection In 5 centers)
0.99: (131 male patients from 18–85 years; were included; with surgical cutaneous lesions with infection In 5 centers)
0.99: (131 male patients from 18–85 years; were included; with surgical cutaneous lesions in danger of infection In 5 centers)
0.99: (131 female patients from 18–85 years; were included; with posttraumatic cutaneous lesions with infection In 5 centers)
0.98: (131 female patients from 18–85 years; were included; with posttraumatic cutaneous lesions in danger of infection In 5 centers)
0.98: (131 female patients from 18–85 years; were included; with surgical cutaneous lesions with infection In 5 centers)
0.99: (131 female patients from 18–85 years; were included; with surgical cutaneous lesions in danger of infection In 5 centers)
0.99: (area; ≥; 200 mm2)

Patients and methods : In 5 centers , 131 male and female patients from 18–85 years were included with posttraumatic or surgical cutaneous lesions with infection or in danger of infection ( area ≥ 200 mm2 ) .
0.99: (131 male patients from 18–85 years; were included; with posttraumatic cutaneous lesions in danger of infection In 5 centers)
0.98: (area; ≥; 200 mm2)
0.94: (131 male patients from 18–85 years; were included; with surgical cutaneous lesions with infection area In 5 centers)
0.99: (131 male patients from 18–85 years; were included; with surgical cutaneous lesions in danger of infection In 5 centers)
0.99: (131 female patients from 18–85 years; were included; with posttraumatic cutaneous lesions with infection In 5 centers)
0.99: (131 female patients from 18–85 years; were included; with posttraumatic cutaneous lesions in danger of infection In 5 centers)
0.94: (131 female patients from 18–85 years; were included; with surgical cutaneous lesions with infection area In 5 centers)
0.99: (131 female patients from 18–85 years; were included; with surgical cutaneous lesions in danger of infection In 5 centers)

This document id is 30240012 .
1.00: (This document id; is; 30240012)

PATIENTS AND METHODS : In 5 study sites , 131 men and women aged 18 to 85 years with a posttraumatic/postoperative infected or infection-prone skin lesion ( wound area ≥ 200 mm2 ) participated .
0.89: (131 men; aged; 18 to 85 years with a posttraumatic/postoperative infected skin)
0.91: (131 men aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ); participated; In 5 study sites)
0.97: (131 men; aged; 18 to 85 years with a infection-prone skin lesion)
0.62: (131 men aged 18 to 85 years with a infection-prone skin lesion ( wound; ≥ participated; In 5 study sites area 200 mm2 ))
0.30: (131 men aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 ); participated; In 5 study sites)
0.97: (131 women; aged; 18 to 85 years with)
0.91: (131 women aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ); participated; In 5 study sites)
0.93: (131 women; aged; 18 to 85 years with a infection-prone skin lesion)
0.60: (131 women aged 18 to 85 years with a infection-prone skin lesion ( wound area; ≥ participated; In 5 study sites 200 mm2 ))
0.23: (131 women aged 18 to 85 years with a infection-prone skin lesion ( wound area ≥ 200 mm2 ); participated; In 5 study sites)
0.92: (131 men; aged; 18 to 85 years with a infected)
0.82: (METHODS 131 men aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ); participated; In 5 study sites)
0.52: (METHODS 131 men aged 18 to 85 years with a infection-prone skin lesion (; ≥ participated; 5 study sites wound area 200 mm2 ) In)
0.26: (131 men aged 18 to 85 years with a infection-prone skin lesion ( wound area 200 mm2; participated; In 5 study sites)
0.98: (131 women; aged; 18 to 85 years)
0.82: (METHODS 131 women aged 18 to 85 years with a posttraumatic/postoperative infected skin lesion ( wound area ≥ 200 mm2 ); participated; In 5 study sites)
0.09: (METHODS 131 women aged 18 to 85 years with a infection-prone skin lesion ( wound; ≥ participated; 5 study sites area 200 mm2 ) In)

This document id is 30240021 .
1.00: (This document id; is; 30240021)

In a double-blind study , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g of vehicle ) or placebo powder ( n = 69 ) was applied to the wound twice daily for 9 days .
0.48: (tyrothricin 0.1 g tyrothricin per 100 g of vehicle; was applied; to the wound In a double-blind study twice daily for 9 days)
0.80: (placebo powder; was applied; to the wound In a double-blind study twice daily for 9 days)

This document id is 30240022 .
1.00: (This document id; is; 30240022)

During 9 days of double-blind treatment , tyrothricin ( n = 62 ; 0.1 g tyrothricin per 100 g base ) or placebo powder ( n = 69 ) was to be applied to the wound area 2 × daily .
0.77: (tyrothricin 0.1 g tyrothricin per 100 g base; was; to be applied to the wound area 2 × daily During 9 days of double-blind treatment)
0.60: (tyrothricin 0.1 g tyrothricin per 100 g base; to be applied; to the wound area 2 daily)
0.85: (placebo powder; was; to be applied to the wound area 2 × daily During 9 days of double-blind treatment)
0.14: (placebo powder; to be applied ×; to the wound area 2 daily)

This document id is 30240031 .
1.00: (This document id; is; 30240031)

The primary aim was to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment ( α = 0.025 ; one-sided ) .
0.91: (The primary aim; was; to evaluate the average daily reduction of the radius from the lesion area between the start and end of the randomized treatment ()

This document id is 30240032 .
1.00: (This document id; is; 30240032)

The primary efficacy parameter was the average daily reduction in wound radius calculated from wound area between the start and end of randomized treatment ( α = 0.025 ; unilateral ) .
1.00: (The primary efficacy parameter; was; the average daily reduction in wound radius)
0.94: (wound radius; calculated; from wound area between the start and end of randomized treatment ( α = 0.025)

This document id is 30240041 .
1.00: (This document id; is; 30240041)

Secondly , a wound index ( range 0–15 ) was calculated from the assessments of rubor , crusting , exudation , pain and functional impairment .
1.00: (a wound index; was calculated; from the assessments of rubor)
1.00: (a wound index; was calculated; from the assessments of crusting)
1.00: (a wound index; was calculated; from the assessments of exudation)
1.00: (a wound index; was calculated; from the assessments of pain)
1.00: (a wound index; was calculated; from the assessments of functional impairment)

This document id is 30240042 .
1.00: (This document id; is; 30240042)

A wound index ( range of values : 0-15 ) was calculated from the assessment of symptoms of redness , coatings , exudation , pain , and functional limitation .
1.00: (A wound index; was calculated; from the assessment of symptoms of redness)
1.00: (A wound index; was calculated; from the assessment of symptoms of coatings)
1.00: (A wound index; was calculated; from the assessment of symptoms of exudation)
1.00: (A wound index; was calculated; from the assessment of symptoms of pain)
1.00: (A wound index; was calculated; from the assessment of symptoms of functional limitation)

This document id is 30240051 .
1.00: (This document id; is; 30240051)

Results : The treatment groups were comparable at baseline .
1.00: (The treatment groups; were; comparable at baseline)

This document id is 30240052 .
1.00: (This document id; is; 30240052)

Results : Wound radius decreased by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the intention-to-treat collective at comparable baseline ( p = 0.016 ; one-sided ) .
0.07: (Wound radius; decreased; by an average of 0.55 ± 0.31 mm/day ( mean ± s ) under tyrothricin and 0.47 ± 0.30 mm/day under placebo in the collective at comparable baseline intention-to-treat)

This document id is 30240061 .
1.00: (This document id; is; 30240061)

During randomized treatment , the radius of the lesions was reduced at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for placebo ( p = 0.016 ; one-sided ; intention-to-treat data set ) .
0.59: (the radius of the lesions; was reduced; at an average of 0.55 ± 0.31 mm/day ( mean ± SD ) for tyrothricin and 0.47 ± 0.30 mm/day for During randomized treatment)
0.80: (one-sided intention-to-treat data; set; )

This document id is 30240062 .
1.00: (This document id; is; 30240062)

The wound index decreased by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo ( p = 0.0048 ; one-sided ) .
1.00: (The wound index; decreased; by a mean of 4.2 ± 1.7 points under tyrothricin and 3.3 ± 1.9 points under placebo)

This document id is 30240071 .
1.00: (This document id; is; 30240071)

The wound index decreased at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin and placebo , respectively ( p = 0.0048 ; one-sided ) .
0.96: (The wound index; decreased respectively; at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for tyrothricin ,)
0.98: (The wound index; decreased respectively; at an average of 4.2 ± 1.7 and 3.3 ± 1.9 points for placebo ,)

This document id is 30240072 .
1.00: (This document id; is; 30240072)

Of 4 adverse events in each of the two treatment groups , a causal relationship with the medication could not be ruled out in only 3 cases under placebo .
1.00: (a causal relationship with the medication; could not be ruled out; in only 3 cases under placebo)

This document id is 30240081 .
1.00: (This document id; is; 30240081)

4 adverse events occurred in each group .
1.00: (4 adverse events; occurred; in each group)

This document id is 30240082 .
1.00: (This document id; is; 30240082)

Conclusions : The results demonstrate the promotion of healing of infected and infection-prone skin lesions by Tyrothricin powder ( Tyrosur® powder ) and its superiority over placebo .
1.00: (The results; demonstrate; its superiority over placebo)
1.00: (The results; demonstrate; the promotion of healing of infected skin lesions by Tyrothricin powder)
1.00: (The results; demonstrate; the promotion of healing of infection-prone skin lesions by Tyrothricin powder)

This document id is 30240091 .
1.00: (This document id; is; 30240091)

A causal relationship with the investigational drug could not be excluded in 3 of the placebo group .
1.00: (A causal relationship with the investigational drug; could not be excluded; in 3 of the placebo group)

This document id is 30240092 .
1.00: (This document id; is; 30240092)

Due to the good tolerability and the lack of a systemic effect , the substance is suitable for therapy in skin injuries .
1.00: (the substance; is; suitable for therapy in skin injuries)

This document id is 30240101 .
1.00: (This document id; is; 30240101)

Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .
0.98: (The results; confirm; the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection)

Conclusion : The results confirm the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of infection or danger of infection .
0.92: (The results; confirm; the tendency to an acceleration of wound healing by tyrothricin powder ( Tyrosur® Powder ) in case of danger of infection)

This document id is 30240111 .
1.00: (This document id; is; 30240111)

A superior efficacy compared to placebo was demonstrated .
1.00: (A superior efficacy; compared; to placebo)
1.00: (A superior efficacy compared to placebo; was demonstrated; )

This document id is 30240121 .
1.00: (This document id; is; 30240121)

Due to its good tolerability and the absence of a systemic effects tyrothricin powder is appropriate for the treatment of superficial skin lesions .
0.99: (tolerability tyrothricin powder; is; appropriate for the treatment of superficial skin lesions)
0.19: (the absence of a systemic effects tyrothricin powder; is; appropriate for the treatment of superficial skin lesions)

This document id is 30250001 .
1.00: (This document id; is; 30250001)

2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted with aromatic amines selectively by substitution at the 5-position to yield the amidines 2 .
0.76: (2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine; reacted selectively; with aromatic amines by substitution at the 5-position)

This document id is 30250002 .
1.00: (This document id; is; 30250002)

2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine ( 1 ) reacted selectively with aromatic amines with substitution at the 5-position to give the amidines 2 .
0.98: (2,5-Dichloro-4-methyl-benzo [ c ] [ 2,7 ] naphthyridine; reacted selectively; with aromatic amines with substitution at the 5-position)

This document id is 30250011 .
1.00: (This document id; is; 30250011)

The 4-aminophenol 2c could also be synthesized by cleavage of the ether 2b .
1.00: (The 4-aminophenol 2c; could also be synthesized; by cleavage of the ether 2b)

This document id is 30250012 .
1.00: (This document id; is; 30250012)

The 4-aminophenol 2c could also be prepared by ether cleavage of 2b .
1.00: (The 4-aminophenol 2c; could also be prepared; by ether cleavage of 2b)

This document id is 30250021 .
1.00: (This document id; is; 30250021)

The structure of 2c was proved by X-ray crystal analysis .
1.00: (The structure of 2c; was proved; by X-ray crystal analysis)

This document id is 30250022 .
1.00: (This document id; is; 30250022)

This document id is 30250031 .
1.00: (This document id; is; 30250031)

Aminomethylation of 2c yielded the amodiaquine analogue 3 .
1.00: (Aminomethylation of 2c; yielded; the amodiaquine analogue 3)

This document id is 30250032 .
1.00: (This document id; is; 30250032)

Aminomethylation of 2c afforded the amodiaquine analogue 3 .
1.00: (Aminomethylation of 2c; afforded; the amodiaquine analogue 3)

This document id is 30250041 .
1.00: (This document id; is; 30250041)

The mono- and bisaminomethylated derivatives 4 and 5 were obtained by reaction of compound 1 with phenol Mannich base hydrochlorides .
1.00: (The mono- derivatives 4; were obtained; by reaction of compound 1 with phenol Mannich base hydrochlorides)
1.00: (The mono- derivatives 5; were obtained; by reaction of compound 1 with phenol Mannich base hydrochlorides)
1.00: (The bisaminomethylated derivatives 4; were obtained; by reaction of compound 1 with phenol Mannich base hydrochlorides)
0.99: (The bisaminomethylated derivatives 5; were obtained; by reaction of compound 1 with phenol Mannich base hydrochlorides)

This document id is 30250042 .
1.00: (This document id; is; 30250042)

Reaction of 1 with phenol Mannich base hydrochlorides gave the mono- and bisaminomethylated derivatives 4 and 5 .
1.00: (Reaction of 1 with phenol Mannich base hydrochlorides; gave; the mono- derivatives 4)
1.00: (Reaction of 1 with phenol Mannich base hydrochlorides; gave; the mono- derivatives 5)
0.99: (Reaction of 1 with phenol Mannich base hydrochlorides; gave; the bisaminomethylated derivatives 4)
0.99: (Reaction of 1 with phenol Mannich base hydrochlorides; gave; the bisaminomethylated derivatives 5)

This document id is 30250051 .
1.00: (This document id; is; 30250051)

Compounds 3–5 were tested in vitro for antimalarial activity using chloroquine-sensitive and resistant Plasmodium-falciparum strains .
0.98: (Compounds 3–5; were tested; in vitro for antimalarial activity)

This document id is 30250052 .
1.00: (This document id; is; 30250052)

Compounds 3-5 were tested for activity against malaria with a chloroquine-sensitive and -resistant Plasmodium falciparum strain in vitro .
0.99: (Compounds 3-5; were tested; for activity against malaria with a chloroquine-sensitive Plasmodium falciparum strain in vitro)
1.00: (Compounds 3-5; were tested; for activity against malaria with a -resistant Plasmodium falciparum strain in vitro)

This document id is 30250061 .
1.00: (This document id; is; 30250061)

The highest activities were shown by the pyronaridine-type compounds 5a and 5b with IC50 values of approximately 200 nM .
0.86: (The highest activities; were shown; by the pyronaridine-type compounds 5a with IC50)
0.91: (The highest activities; were shown; by the pyronaridine-type compounds 5b IC50)

This document id is 30250062 .
1.00: (This document id; is; 30250062)

Pyronaridine analogues 5a and 5b showed the best activities with IC50 values around 200 nM .
0.98: (Pyronaridine analogues 5a; showed; the best activities with IC50 values around 200 nM)
0.98: (Pyronaridine analogues 5b; showed; the best activities with IC50 values around 200 nM)

